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the complete set of treatments that may be used in the patient group
under consideration. Randomized controlled trials are a key source of
evidence for these comparisons. The techniques of network meta-
analysis allow the networks of trial evidence to be evaluated to obtain
estimates of comparative efﬁcacy between sets of treatments. These
techniques may be the only source of estimates of comparative
effectiveness if trials directly comparing the treatments of interest
have not been conducted, and may provide useful additional evidence
if both direct and indirect comparisons exist. Methods: We examined
both published and draft guidelines from reimbursement and health
technology appraisal bodies, and considered their recommendations
using appropriate methodology for the conduct of indirect comparisonsee front matter Copyright & 2014, International S
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ondence to: Andrew Laws, ICON Health Economics,and the assessments of their validity. Results: Guidelines from 33
countries were reviewed. Of these, guidelines from 9 countries—
Australia, Belgium, Canada, France, Germany, Scotland, Spain, South
Africa, and the United Kingdom (England and Wales)—included
detailed recommendations on the conduct of network meta-analysis.
The recommendations were summarized. Conclusions: No two rec-
ommendations from the multiple national guidelines are mutually
exclusive. It is possible to perform one network meta-analysis for
submission to multiple national jurisdictions.
Keywords: guidelines, meta-analysis, policy, reimbursement.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The development of meaningful clinical treatment guidelines
and reimbursement policies entails comparisons of all competing
treatment interventions. Some commentators consider system-
atic reviews of randomized controlled trials (RCTs) to provide the
highest level of evidence for evidence-based decision making [1].
RCTs that simultaneously compare all interventions, however,
are rarely available in therapeutic areas with multiple treatment
options [2].
Standard pairwise meta-analyses include studies that compare
the same two treatments. A network meta-analysis (NMA) extends
the analysis to include a network of pairwise comparisons across a
range of different interventions and provides estimates of com-
parative effectiveness for multiple treatments. NMAs are often
performed if direct comparisons are unavailable; however, they
can also make valuable contributions to the overall body of
evidence even when direct comparisons are available by providing
estimates based on a combination of direct and indirect evidence
[3–7]. National regulatory and reimbursement agencies around the
world increasingly regard NMA as a key part of the health care
decision-making process. Several countries have released guide-
lines describing their requirements for such an assessment, or
developed review documents highlighting the current best prac-
tice to inform organizations preparing submissions.There is currently a lack of literature comparing national
submission requirements for NMA. The International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) has devised
an online tool for comparing submission guidelines [8]; however,
at present it does not include information comparing the conduct
of NMAs. Given the transnational nature of therapeutic interven-
tions, and the need for pharmaceutical manufacturers to apply to
multiple national jurisdictions to gain regulatory and market
access for their products, there is a clear need for the develop-
ment of a “super set” of requirements that would facilitate the
conduct of NMAs acceptable in multiple jurisdictions. The ability
to create a single analysis that is acceptable in multiple juris-
dictions has the potential to reduce costs for manufacturers and
time-to-market for new interventions.Methods
Identiﬁcation of Relevant Documents
The sampling frame for the search of national guidelines com-
pared in this review was the countries listed in the Web-based
repository of country-speciﬁc pharmacoeconomic guidelines
maintained by ISPOR [8]. As of July 22, 2013, this comprised
guidelines from 33 countries: Australia, Austria, Baltic statesociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 4 2 – 6 5 4 643(Latvia, Lithuania, and Estonia), Belgium, Canada, China, Cuba,
Denmark, England and Wales, Finland, France, Germany, Hun-
gary, Ireland, Israel, Italy, Mexico, New Zealand, The Netherlands,
Norway, Poland, Portugal, the Russian Federation, Scotland,
Slovak Republic, South Africa, South Korea, Sweden, Thailand,
Taiwan, and the United States.
The ISPOR repository separates guidelines into three catego-
ries: Published Pharmacoeconomic Recommendations (economic
evaluation guidelines or recommendations published by experts
in the ﬁeld but not ofﬁcially recognized or required by health care
decision-making bodies); Pharmacoeconomic Guidelines (ofﬁcial
guidelines or policies concerning economic evaluation that are
recognized or required by health care decision-making bodies);
and Submission Guidelines (ofﬁcial guidelines or policies con-
cerning drug submission requirements with an economic evalu-
ation component). Documents from all three categories were
considered in this review. In addition, working papers and other
methodological reports (including the ISPOR task force report on
the conduct of indirect comparisons because this was referenced
by a number of guidelines) [9], Web sites, and other listed sources
were checked to ensure that the most recent versions of docu-
ments were reviewed. To this end, documents in draft were also
included in this review. For the purposes of this review, docu-
ments were classiﬁed as either guidelines or methods reviews.
Guidelines or methods reviews were screened for references
to indirect comparisons or NMA, with documents from 14 of the
33 countries included in the review containing references to the
use, conduct, or reporting of NMA. Of these, guidelines from ﬁve
countries (Ireland, Norway, Poland, Sweden, and the United
States) made reference to the potential use of indirect compar-
isons in technology appraisals but did not provide any further
detailed guidance as to their conduct and reporting. For example,
the Irish guidelines stated that “In the event of limited head-to-
head RCT data, mixed treatment comparisons can be used” [10],
the United States’ Academy of Managed Care Pharmacy guidance
mentions indirect comparisons under the heading of “Other
Supporting Evidence” and noted that “Today, network meta-
analyses are becoming more relied on and accepted as valid
means to compare interventions” [11], and the Swedish guide-
lines issued by Tandvårds-och läkemedelsförmånsverkets före-
skrifter contained very few requirements, and instead referenced
the ISPOR task force report [12]. Documents from the remaining
nine countries (Australia, Belgium, Canada, England and Wales,
France, Germany, Scotland, Spain, and South Africa) provided
more detailed guidance, which is summarized in this article.
These documents are summarized in Table 1.
Comparison of National Guidelines
The national guidelines were initially reviewed, and checklists
were developed to summarize their recommendations. These
checklists were completed for each of the guidelines by two
separate reviewers. A ﬁnal review of the guidelines was con-
ducted and any additional items required were added to the
checklists. Finally, the checklists were compared across
reviewers and any discrepancies were resolved.Results
The recommendations made in the guidelines are described
under the following headings: clinical trial search, selection of
databases, study selection, bias assessment, and conduct of NMA.
Each heading comprises a number of potential recommenda-
tions. For each recommendation, we have noted whether it is
referred to in the corresponding national guideline; we make no
distinction between a “recommendation” and a “requirement.”Clinical Trial Search
The ﬁrst step in carrying out an NMA is to identify the clinical
trials that may potentially form the network of comparisons.
Table 2 details recommendations regarding the design, conduct,
and reporting of the trial search. These recommendations can be
divided into four categories: 1) Deﬁnition of search time frame;
this allows regulators to assess whether the time frame is
adequate; 2) Predeﬁnition of search parameters; typically the
population(s), intervention(s), comparator(s), outcome(s), study
design approach to reporting studies [13]. This improves trans-
parency and increases conﬁdence in the study ﬁndings; 3) Clear
description of search conduct; most of the national guidelines
require that the search strategy be presented in full with all the
terms and relationships documented, and many guidelines
require a ﬂow diagram with “n” returns at each step; and 4)
Manually checking reference lists in identiﬁed articles to increase
the sensitivity of the search.
There is an overall focus on the transparency and repeat-
ability of the search. Canada and England and Wales require that
the search complies with best-practice guidelines issued by the
Centre for Reviews and Dissemination [14,15]. Germany requires
that keywords, MeSH identiﬁers, and other terms used to search
electronic databases be grouped into related blocks in the
presentation of the search strategy [16].
Selection of Databases
Most of the national pharmacoeconomic guidelines specify
which databases should be searched. Table 3 lists the various
databases listed in the national guidelines. MEDLINE, EMBASE,
and the Cochrane (CENTRAL) databases form a core speciﬁed by
almost all the national guidelines. Outside of this core there is
variation, with some jurisdictions requiring that the search be
conducted in databases with a local focus and others requiring
more emphasis on clinical trial databases. Four of the nine
national guidelines require that the search be conducted in an
international registry of clinical trials, either clinicaltrials.gov or
the International Clinical Trials Registry Platform, but typically
both [14–17]. The German guideline references the industry-
maintained clinicalstudyresults.org database, which has been
closed since the publication of the German guidelines [16]. The
national guideline document issued by the Australian Pharma-
ceutical Beneﬁts Advisory Committee requires that the Australia
New Zealand Clinical Trials Registry form part of the search
strategy [17]. The Australia New Zealand Clinical Trials Registry
forms part of the International Clinical Trials Registry Platform
search portal that is required by other national guidelines;
however, the Pharmaceutical Beneﬁts Advisory Committee spe-
ciﬁcally differentiates between the two. German and Australian
guidelines require that company-speciﬁc databases be searched
and results presented, although the national guidelines contain
no indication how the transparency and repeatability of such a
search would be enforced [16,17].
The French, Scottish, and Spanish guideline documents do
not contain recommendations or requirements regarding the
search strategy to be implemented or databases searched [18–
20] (A. Ortega, M. Fraga, E. Alegre, et al., personal communication,
2013). The French methods review document does provide details
of the search strategy used in the review document itself, but not
for identifying trials as part of an NMA.
Study Selection
Following the completion of the search, it is necessary to
determine which studies should be included in the NMA. The
requirements for the study selection process are listed in Table 4.
In many cases, they are less rigorous than the methods
Table 1 – Summary of national guidelines.
Nation Body Document title Year
published
Authors Guideline or method
review
Australia Pharmaceutical Beneﬁts
Advisory Committee
(PBAC)
Guidelines for preparing
submissions to the
Pharmaceutical Beneﬁts
Advisory Committee (version
4.3) [17]
2008 NS Guideline þ methods review
PBAC Indirect Comparisons
Working Group
Report of the Indirect
Comparisons Working Group
to the Pharmaceutical Beneﬁts
Advisory Committee:
assessing indirect
comparisons [30]
2008 Carlin J, Coory M, Deﬁna J,
Eckermann S, Frauman A,
Hunt L, McCloud P, McColl G,
Sansom L, Viney R, Yuen C
Guideline þ methods review
Belgium Federaal Kenniscentrum voor
de Gezondheidszorg
Centre fédéral d’expertise
des soins de santé (KCE)
Guidelines for
pharmacoeconomic
evaluations in Belgium KCE
reports 78C [24]
2008 Cleemput I, Van Wilder P,
Vrijens P, Huybrechts M,
Ramaekers D
Guideline
Canada Canadian Agency for Drugs
and Technology in Health
(CADTH)
Indirect evidence: indirect
treatment comparisons in
meta-analysis [28]
2009 Wells GA, Sultan SA, Chen L,
Khan M, Coyle D
Methods review
CADTH Guidelines for the economic
evaluation of health
technologies: Canada [14]
2006 Contandriopolous AP, Hailey D,
Mamdani M, Coyle D, Jacobs P
England and
Wales
National Institute for Health
and Care Excellence (NICE)
Guide to the methods of
technology appraisal 2013 [15]
2013 NS Guideline
France Collège des Èconomistes de
la Santè
French guidelines for the
economic evaluation of health
care technologies [19]
2004 Boulenger S, Ulmann P Guideline
Haute Autorité de Santé
(HAS)
Indirect comparisons— methods
and validity [18]
2009 Cucherat M, Izard V Methods review
Germany Gemeinsamer
Bundesausschuss
Dossier for the Beneﬁt
Assessment pursuant to
Section 35a of the German
Social Code Book Five –
Module 4 [16]
2011 NS Guideline
Scotland Scottish Medicines
Consortium (SMC)
Guidance to manufacturers for
completion of New Product
Assessment Form (NPAF) [20]
2013 NS Guideline
South Africa Department of Health:
Directorate PEE
The guidelines for
pharmacoeconomic
evaluations of medicine and
scheduled substances [23]
2013 NS Guideline
Spain 2013 Methods review
continued on next page
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GENESIS Group of the
Spanish Society of Hospital
Pharmacy (SEFH)
A check-list for critical appraisal
of indirect comparisons
(A. Ortega, M. Fraga, E. Alegre,
et al., personal
communication, 2013)
Ortega A, Fraga MD, Alegre E,
Puigventos F, Porta MA,
Ventayol P
ISPOR International Society for
Pharmacoeconomics and
Outcomes Research
Conducting indirect treatment
comparison and network
meta-analysis studies: report
of the ISPOR Task Force on
Indirect Treatment
Comparisons Good Research
Practices: part 2 [9]
2011 Hoaglin DC, Hawkins N, Jansen
JP, Scott DA, Itzler R,
Cappelleri JC, Boersman C,
Thompson D, Larholt HM,
Diaz M, Barrett A
Methods review
ISPOR International Society for
Pharmacoeconomics and
Outcomes Research
Indirect treatment comparison/
network meta-analysis study
questionnaire to assess
relevance and credibility to
inform healthcare decision
making: an ISPOR-AMCP-NPC
Good Practice Task Force
Report [31]
2014 Jansen JP, Trikalinos T,
Cappelleri JC, Andes S, Daw
J, Andes S, Eldessouki R,
Salanti G
Methods review
Ireland An tÙdaràs Um Fhaisnèis
agus Càiliocht Slàinte
Guidelines for the Economic
Evaluation of Health
Technologies in Ireland. [32]
2010 NS Guideline
Norway Statens legemiddelverk Guidelines on how to conduct
pharmacoeconomic analyses
[33]
2012 NS Guideline
Poland Agencja Oceny Technologii
Medyczncyh
Guidelines for conducting health
technology assessment (HTA)
[34]
2009 Agencja Oceny Technologii
Medyczncyh
Guideline
Sweden Tandvårds- och
läkemedelsförmånsverket
Handbok till Tandvårds- och
läkemedelsförmansverkets
föreskrifter (TLVFS 2011:3) om
ansökan om pris och
subvention för
förbrukningsartiklar [12]
NS Guideline
United
States
Academy of Managed Care
Pharmacy (AMCP)
The AMCP format for formulary
submissions version 3.1 [11]
2012 AMCP Format Executive
Committee and Working
Group
Guideline
ISPOR, International Society for Pharmacoeconomics and Outcomes Research; NS, not speciﬁed.
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Table 2 – Recommendations regarding the design, conduct, and reporting of trial searches.
Country Report
date(s)
search
conducted
Specify
search
date
span
Specify
PICO
criteria
Justify
restrictions,
e.g.,
language
and
years
searched
Describe
search
terms and
relationship
Present
strategy
in blocks by
indication,
intervention,
study type,
etc.
Perform
supplementary
searches/
manual
checking
Present
PRISMA-
type
diagram
showing
study
disposition
Conduct search
in accordance
with CRD
systematic
review
procedures
Australia    
Belgium   
Canada        
England and Wales        
France*
Germany    
Scotland      
South Africa    
Spain   
ISPOR Task
Force Best
Practice Guide
       
ISPOR NMA
Assessment
Questionnaire

CRD, Centre for Reviews and Dissemination; NMA, network meta-analysis: PICO, Patient-Intervention-Comparator-Outcome; PRISMA, Preferred Reporting Items for Systematic Reviews and
Meta-Analyses.
* The French methods review document contains details of a search strategy used for that review, but not for reviews in general.
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Table 3 – Speciﬁed databases.
Country MEDLINE Embase Cochrane
(CENTRAL)
Cochrane
Database
of
Systematic
Reviews
Clinicaltrials.
gov
Clinicalstudyresults.
org *
ICTRP
search
portal
NHS
CRD
ANZCTR Subject-
speciﬁc
databases
or
registers †
Manufacturers’
internal
databases
Australia      
Belgium     
Canada      
England and
Wales
     
France
Germany        
Scotland
South Africa    
Spain
ISPOR Task
Force Best
Practice
Guide
     
ISPOR NMA
Assessment
Questionnaire
   
ANZCTR, Australia New Zealand Clinical Trials Registry (formerly the Australia Clinical Trials Registry); CENTRAL, Cochrane Central Register of Controlled Trials; CRD, Centre for Reviews and
Dissemination; EED, Economic Evaluation Database; HEED, Health Economic Evaluation Database; ICTRP, International Clinical Trials Registry Platform; ISPOR, International Society for
Pharmacoeconomics and Outcomes Research; NHS, National Health Service; NMA; network meta-analysis.
* Database decommissioned Q4 2011.
† For example, PsycINFO (psychology and psychiatry), MANTIS (osteopathy and chiropractic), CINAHL (nursing and allied health).
V
A
L
U
E
IN
H
E
A
L
T
H
1
7
(2
0
1
4
)
6
4
2
–
6
5
4
647
Table 4 – Study selection.
Country Selection process Trials include
Predeﬁned
inclusion/
exclusion
criteria
process
Justiﬁed
selection
criteria
Selected by
two
independent
reviewers
Maintained
log of trials
deemed
ineligible
Trials form one
connected
network of
interventions
Randomized
allocation*
Separate
arms*
Demographic
homogeneity
between trials
Similar
prognostic
severity
Australia     
Belgium  
Canada   
England and
Wales
   
France 
Germany  
Scotland     
South Africa  
Spain     
ISPOR Task
Force Best
Practice
Guide
  
ISPOR NMA
Assessment
Questionnaire
    
ISPOR, International Society for Pharmacoeconomics and Outcomes Research; NMA, network meta-analysis.
* Criteria for randomized controlled trials (RCTs).
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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 4 2 – 6 5 4 649recommended by either the Centre for Reviews and Dissemina-
tion (CRD) and the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses [13,21], with less than half of all
national guidelines stipulating explicitly that two reviewers
should carry out the selection process.
Almost all national guidelines specify that inclusion and
exclusion criteria must be deﬁned beforehand. This is crucial
not only to inform the initial search but also to ensure that
selection bias is reduced and all appropriately designed studies
are included regardless of direction or magnitude. Aside from this
consistently applied criterion, there are few proscriptions to the
study selection process; and apart from the Australian guidelines,
there are few requirements as to the design of the studies
themselves. The guidelines from the Pharmaceutical Beneﬁts
Advisory Committee require clinical trials included in the meta-
analysis to have randomized allocation to separate arms, which
are themselves criteria for an RCT [17].
Bias Assessment
Estimates of treatment effect obtained from NMAs may be biased
by the effects of heterogeneity between studies. Table 5 presents
the recommended steps taken to assess the potential for bias
within NMAs. Almost all national guidelines require an assess-
ment of the adequacy of blinding and that the results of the
analysis of the intent-to-treat population are used in the analysis.
Also, an assessment of variance between trial protocol and
standard practice, and comparison of rates of dropout between
the arms of the study, is widely required.
The two French guideline documents do not contain require-
ments for this aspect of NMA beyond a recommendation that
publication bias can be reduced by accessing a clinical trials
registry and including all trials carried out [18,19]. German and
South African guidelines include unique requirements such as
describing included studies according to Consolidated StandardsTable 5 – Bias assessment.
Source of
bias
Identiﬁcation and selection of
studies
National
guideline
Assess level
of bias within
included
studies
Homogeneity
of prognostic
severity
Describe the
and method
according to
CONSORT g
Australia
Belgium 
Canada 
England and
Wales

France
Germany   
Scotland 
South Africa
Spain 
ISPOR Task
Force Best
Practice Guide
ISPOR NMA
Assessment
Questionnaire

CONSORT, Consolidated Standards of Reporting Trials; ISPOR, Internati
intent to treat; NMA, network meta-analysis.of Reporting Trials guidelines [22], or noting the time horizon of
included studies, respectively [16,23]. Australia and Scotland both
require demographic homogeneity between trials [17,20]. In addi-
tion, German regulators require that the level of bias in studies be
assessed, with the stipulation that studies assessed as being
biased must not be excluded [16]. The ISPOR NMA assessment
questionnaire and the National Institute for Health and Care
Excellence Guide to Technology Appraisal are the only documents
that recommend that treatment effect modiﬁers be identiﬁed
before comparing the results of individual studies [2,15].
Conduct of NMA
Table 6a and 6b is a breakdown of the statistical techniques,
processes, and recommended scales for data required by the
national guidelines. It is important to note the relative consis-
tency in the scales preferred. All national guidelines call for a core
set of scales for binary or time-to-event data comprising relative
risk, relative risk difference, hazard ratio, odds ratio, or a
combination thereof. The Spanish guidelines do not contain
any recommendations as to the type of scales to be used for
data. France, Scotland, and Spain recommend meta-regression to
be performed. Where continuous data are reported, the national
guidelines are split four to three on whether to use median
difference or weighted mean difference, respectively, with South
Africa and Spain having no speciﬁc requirements. Even though
naive indirect comparisons, where the results of individual arms
of different trials are compared as though they were from the
same trial, produce evidence equivalent only to observational
studies, over half the countries considered it necessary to
explicitly prohibit their conduct [15,16,19,25] (A. Ortega, M. Fraga,
E. Alegre, et al., personal communication, 2013).
None of the national guidelines stipulated what form sensi-
tivity analyses should take, but seven of the nine national
jurisdictions require descriptions and rationale for sensitivityConduct and reporting of clinical trials
design
ology
uidelines
Assessment of
variance between
trial protocol
and standard
practice
Assess
adequacy
of blinding
Comparison
of dropout
rates
 
  
  
  


 
 
 
onal Society for Pharmacoeconomics and Outcomes Research; ITT,
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 4 2 – 6 5 4650analyses, with ﬁve countries subsequently requiring a description
of the different ﬁndings and three needing a relative effect
estimate. France, Germany, Scotland, Spain, and Australia
require an assessment of the heterogeneity of direct compari-
sons, with Germany, Scotland, Spain, and Australia also requiring
that a Cochrane Q test be performed [16,17,19]. Most of the
countries call for a consistency check between direct and indirect
evidence, strongly suggesting that indirect evidence should be
considered as an adjunct to direct evidence. None of the national
guidelines indicated that differences between direct and indirect
evidence would render indirect evidence inadmissible.
Very few aspects of the conduct of the analysis were required
only by a single country. Perhaps surprisingly, only the German
and Scottish regulators require a network diagram showing the
links between the studies. Germany is also the only country to
explicitly request the inclusion of any code and the software
package used [16].Discussion
For the ﬁrst time, multiple national guideline documents have
been compared with each other and the differing stipulations on
the conduct of indirect comparisons extracted. The technique of
indirect NMA is recent in the ﬁeld of health technology assess-
ment. This combination of relative novelty and the precedent of
individual national regulatory bodies having jurisdiction over
their respective markets means that there are currently no
transnational guidelines for the compilation of indirect evidence.
ISPOR has published multiple best-practice documents to inform
practitioners and regulators [9,26,27]. Although these documents
were comprehensive when their collective recommendations
were combined, they did not capture every nuance of the process
of NMA required by every national regulatory body. By using the
aggregated recommendations from the tables herein, it becomesTable 5 – continued
Conduct and reporting of clinical
National
guideline
Implemen-
tation of
ITT
Assessment
of difference
in baseline
risk and
placebo
response
Describe
time
horizon
Australia  
Belgium 
Canada 
England and Wales 
France
Germany 
Scotland
South Africa   
Spain 
ISPOR Task Force Best
Practice Guide
 
ISPOR NMA
Assessment
Questionnairepossible to create a super set of recommendations that will
satisfy the regulatory bodies considered.
There is an overall focus on the transparency and repeat-
ability of the search process. Certain jurisdictions such as South
Africa will conduct a search of their own to mirror that of the
submission and will suspend the application if any relevant
studies are found to have been omitted [23]. All national guide-
lines reviewed that consider the systematic review component of
NMA require that a search be conducted in MEDLINE, EMBASE,
and the Cochrane (CENTRAL) databases, with certain regulatory
bodies requiring that additional databases searched be nationally
or regionally speciﬁc.
The task of complying with a “one-size-ﬁts-all” super set of
requirements is made more onerous by having to perform tasks
required by only a single country, although only a handful of
these instances were noted. For example, only Germany requires
that the design and methodology of the studies be described
according to Consolidated Standards of Reporting Trials guide-
lines; however, this becomes a requirement for the super set.
Although the Australian guidelines appear to place proscriptions
on trial selection, the requirement that trials included in the
meta-analysis have randomized allocation to separate arms is
reﬂective of standard RCT practice. The requirement for demo-
graphic homogeneity between trial populations is reﬂected in the
national guidelines of Belgium, Canada, England and Wales,
Germany, Scotland, and Spain, which all require that there be
homogeneity of prognostic severity between trials as part of their
bias assessment.
It is notable that there is an overall lack of explicit require-
ments regarding an assessment of the distribution of treatment
effect modiﬁers across studies included in the NMA. An imbal-
ance in the effect modiﬁers between the direct comparisons
suggests that the transitivity assumption may have been vio-
lated. Transitivity in this context means that if treatment A is
ranked above treatment B in terms of efﬁcacy, and B is rankedtrials Network meta-analysis
Investigator
conﬂicts of
interest
reported
Report of
subgroup
analysis
Treatment
effect
modiﬁers
identiﬁed
before
comparing
study results
Assessment
of
publication
bias and/or
funnel plot


 



 
  
T
ab
le
6a
–
C
o
n
d
u
ct
o
f
in
d
ir
ec
t
co
m
p
ar
is
o
n
s.
C
ou
n
tr
y
C
on
d
u
ct
of
in
d
ir
ec
t
co
m
p
ar
is
on
Descriptionofpatient&treatmentcharacteristics
Describe&justifystatisticalmethod;BayesianorFrequentist
IBayesian;describepreviousdistribution;
sensitivitytoprevious;andassessconvergence
Presentindividualstudyresultsand=orforestplot
Graphicallysummarizerankprobabilities
Descriptionofrelativeeffectestimate
Includerationalefor;anddescriptionof;sensitivityanalyses
Descriptionofdifferentfindingswithsensitivity=scenarioanalysis
Metaregression
Poissondistribution
Naivecomparisonsofpointestimatesoractivearmsareprohibited
Includeanalysisofthehypothesisofconsistency
Assesstheresultsforeachcommonreferenceacrosstrials
foranyimportantdifferences
Performconsistencycheckbetweendirectandindirectevidence
Assesshomogeneityofdirectcomparisons
AssessheterogeneitywithCochraneQ;I
2
Randomeffects
Includecodeandspecifysoftwarepackage
Includediagramofnetworkstructure
A
u
st
ra
li
a





B
el
gi
u
m


C
an
ad
a







En
gl
an
d
an
d
W
al
es










Fr
an
ce








G
er
m
an
y













Sc
o
tl
an
d










So
u
th
A
fr
ic
a







Sp
ai
n









IS
PO
R
T
as
k
Fo
rc
e
B
es
t
Pr
ac
ti
ce
G
u
id
e









IS
PO
R
N
M
A
A
ss
es
sm
en
t
Q
u
es
ti
o
n
n
ai
re













V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 4 2 – 6 5 4 651
T
ab
le
6b
–
Pr
es
en
ta
ti
o
n
o
f
re
su
lt
s.
C
ou
n
tr
y
Pr
es
en
ta
ti
on
of
re
su
lt
s
MediandifferenceðcontinuousÞ
WeightedmeandifferenceðcontinuousÞ
Relativerisk
Hazardratio
Oddsratio
Relativeriskdifference
Absoluteriskreductions
A
u
st
ra
li
a





B
el
gi
u
m



C
an
ad
a





En
gl
an
d
an
d
W
al
es

*
*
*
*
Fr
an
ce





G
er
m
an
y


Sc
o
tl
an
d


So
u
th
A
fr
ic
a





Sp
ai
n
IS
PO
R
T
as
k
Fo
rc
e
B
es
t
Pr
ac
ti
ce
G
u
id
e




IS
PO
R
N
M
A
A
ss
es
sm
en
t
Q
u
es
ti
o
n
n
ai
re
H
R
,h
az
ar
d
ra
ti
o
;I
SP
O
R
,I
n
te
rn
at
io
n
al
So
ci
et
y
fo
r
Ph
ar
m
ac
o
ec
o
n
o
m
ic
s
an
d
O
u
tc
o
m
es
R
es
ea
rc
h
;N
IC
E,
N
at
io
n
al
In
st
it
u
te
fo
r
H
ea
lt
h
an
d
C
ar
e
Ex
ce
ll
en
ce
;N
M
A
,n
et
w
o
rk
m
et
a-
an
al
ys
is
;O
R
,o
d
d
s
ra
ti
o
;
R
R
,
re
la
ti
ve
ri
sk
.
*
M
en
ti
o
n
ed
ex
p
li
ci
tl
y
in
th
e
20
08
N
IC
E
gu
id
e
to
th
e
m
et
h
o
d
s
o
f
te
ch
n
o
lo
gy
ap
p
ra
is
al
[3
1]
.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 4 2 – 6 5 4652
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 4 2 – 6 5 4 653above treatment C, then A must be ranked above C [28]. Despite
the lack of explicit requirements, some guidelines do address the
problem implicitly; the National Institute for Health and Care
Excellence guidelines require that potential treatment effect
modiﬁers be identiﬁed before analysis, and the Belgian guidelines
state that treatment effect may be inﬂuenced by factors that vary
across trials as an example of unacceptable confounding bias [25].
In addition, six of the national guidelines require that an assess-
ment of the homogeneity of direct comparisons be performed,
effectively assessing the potential for treatment effect modiﬁers
to bias results [15,16,20,23,29] (A. Ortega, M. Fraga, E. Alegre, et al.,
personal communication, 2013); however, only England and
Wales require that such modiﬁers be identiﬁed in advance [15].
The strengths of our approach include the process of double
extraction by two reviewers with ﬁnal checking by a third
reviewer, the multistage iterative process of extraction, and the
validation steps leading to consensus building.
A critical limitation is the lack of a searchable database for
national guidelines. This review has gathered documents from
multiple sources including the increasingly comprehensive ISPOR
repository, but the difﬁculty in searching for and accessing
guideline documents means that it cannot be certain that all
relevant documents are represented herein.
The limitations of the original documents were a lack of a shared
vocabulary of technical terms that occasionally resulted in overlap of
requirement categories. Despite locating a guideline document from
the French College Des Economistes de la Santé and a French-based
method review [18,19], neither document contained speciﬁc infor-
mation on study search and selection or bias assessment, nor did
they indicate that there were no requirements, making it difﬁcult to
guarantee compliance with French submission requirements. Sec-
ond, the fact that the German guidelines include the now-defunct
clinicalstudyresults.org database highlights the difﬁculties inherent
in maintaining living guidelines to a rapidly changing ﬁeld in the
Internet age [16]. Potential weaknesses in our analysis come from the
availability of national guidelines. Only nine stipulate the conduct of
NMA in sufﬁcient detail to make comparison viable, and all these are
from either European or Commonwealth countries.
Further work should focus on the requirements from sub-
stantial existing markets not covered, such as Japan and South
Korea, and emerging markets such as Brazil and India.
For the ﬁrst time, guidelines for the use of indirect evidence
from multiple national jurisdictions have been reviewed and the
requirements compiled. The aggregate requirements do not
include requirements that are mutually prohibitive. Subse-
quently, it is now possible to perform one NMA for submission
to multiple national jurisdictions.
Source of ﬁnancial support: The authors have no other
ﬁnancial relationships to disclose.
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